Trolamine salicylate

Identification

Name
Trolamine salicylate
Accession Number
DB11079
Type
Small Molecule
Groups
Approved
Description

Trolamine salicylate is an organic compound or a salt formed between triethanolamine and salicylic acid. Triethanolamine neutralizes the acidity of the salicylic acid. It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises. Unlike other topical analgesics, trolamine salicylate has no distinct odor which improves patient acceptability [2]. It also displays low systemic absorption upon dermal or topical administration [3] and has low skin irritant properties [4]. As with other salicylates, trolamine salicylate is an inhibitor of cyclo-oxygenase (COX) enzymes with no reported selectivity towards a specific enzyme isoform. Trolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary management of mild to moderate muscular and joint pains.

Structure
Thumb
Synonyms
Not Available
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Actiflex Pain Relief RubCream10 %TopicalPendopharm Division Of De Pharmascience Inc2003-01-202011-09-30Canada
Alcis Daily Relief Pain ReliefCream10 g/100mLTopicalAlcis Topical, Inc.2009-03-09Not applicableUs
Alcis Topical Pain Relief CreamCream10 %TopicalAlcis Health Inc.Not applicableNot applicableCanada
AnalgesicCream10 g/100gTopicalMeijer Distribution1990-04-152017-11-22Us
Analgesic CreamCream15 %TopicalPharmascience Inc2013-10-08Not applicableCanada
Analgesic Cream Extra Strength OdorlessCream15 %TopicalPharmascience Inc1999-10-09Not applicableCanada
Analgesic Creme RubCream100 mg/gTopicalMajor2014-05-10Not applicableUs
Antiphlogistine Rub A-535 No Odour Fmla OntOintment13.3 %TopicalCarter Products, Division Of Carter Wallace Ns Inc.1993-12-311997-08-14Canada
ArthricreamCream10 g/100gTopicalWalmart Stores2009-04-25Not applicableUs
ArthricreamCream10 g/100gTopicalKroger1992-02-04Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Arthritis Extra Strength Roll-ON LotionTrolamine salicylate (10 %) + Capsaicin (0.035 %) + Menthol (1.25 %)LotionTopicalChurch & Dwight Company, Inc.2008-09-15Not applicableCanada
Arthur Itis CreamTrolamine salicylate (10 %) + Capsaicin (0.025 %)CreamTopicalNabtech Pharma Inc.1997-09-262005-09-20Canada
Ease Pain Away Analgesic LotionTrolamine salicylate (10 %) + Menthol (1.25 %)LotionTopicalRmc Group Inc.1994-12-311999-11-23Canada
ELF Flawless Finish Foundation SPF 15 Oil FreeTrolamine salicylate (2 g/100g) + Titanium dioxide (5.5 g/100g)CreamTopicalJ. A. Cosmetics U.S. INC2011-10-03Not applicableUs
Myoflex Extra Strength IceTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalBayer Inc Consumer Care2003-10-302007-08-02Canada
Myoflex Ice Cold Plus - GelTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalSterling Winthrop Inc.1994-12-311996-09-10Canada
Myoflex Ice Cold Plus - GelTrolamine salicylate (15 %) + Menthol (3 %)GelTopicalBayer Inc Consumer Care1996-09-101997-08-01Canada
Myoflex Ice Plus - CrmTrolamine salicylate (15 %) + Menthol (3 %)CreamTopicalBayer Inc Consumer Care1994-12-302004-06-28Canada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Permavan External PatchTrolamine salicylate (10 g/100g) + Dextromethorphan hydrobromide (4 g/100g) + Lidocaine (4 g/100g)PatchTopicalHome Aide Diganostics, Inc.2015-03-09Not applicableUs
Categories
UNII
H8O4040BHD
CAS number
2174-16-5
Weight
Average: 287.312
Monoisotopic: 287.1368874
Chemical Formula
C13H21NO6
InChI Key
UEVAMYPIMMOEFW-UHFFFAOYSA-N
InChI
InChI=1S/C7H6O3.C6H15NO3/c8-6-4-2-1-3-5(6)7(9)10;8-4-1-7(2-5-9)3-6-10/h1-4,8H,(H,9,10);8-10H,1-6H2
IUPAC Name
2-[bis(2-hydroxyethyl)amino]ethan-1-ol; 2-hydroxybenzoic acid
SMILES
OCCN(CCO)CCO.OC(=O)C1=CC=CC=C1O

Pharmacology

Indication

Indicated for the temporary relief of aches, and pains of muscles and joints associated with backache, lumbago, strains, bruises, sprains and arthritic or rheumatic pain, pain of tendons and ligaments [6].

Pharmacodynamics

Trolamine salicylate is a salicylate that inhibits cyclo-oxygenase (COX) enzymes responsible for generating pro-inflammatory factors such as to induce pain and inflammation. It is thought to mediate its analgesic effect through inhibition of COX-2 enzyme, which is an induced enzyme responsible for inflammatory responses and pain in muscle and joint disorders. By inhibiting fatty acid COX enzyme, trolamine salicylate inhibits the production of prostaglandins and thromboxanes in inflammatory cells involved in generating pain and inflammation [5]. It thereby works to temporarily reduce mild to moderate pain. In subjects with muscle soreness from exercise, administration of topical trolamine salicylate was associated with reduced duration and severity of muscule soreness compared to placebo [2]. In subjects with osteoarthritis in hands, trolamine salicylate cream was shown to be effective in achieving temporary relief of minor pain and stiffness [1].

Mechanism of action

Inflammation and tissue damage in different conditions including arthritis, bursitis, joint disorder, bruises, and strains or sprains of muscle origin, induce mild to moderate pain and are associated with increase prostaglandin synthesis [5]. This is thought to be a result of COX-2 enzyme induction. COX-2 is induced in inflammatory cells in case of cell injury, infection or activation from inflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-α. Upon activation, COX-2 produces prostanoid mediators of inflammation such as prostaglandins and thromboxanes [5]. Trolamine salicylate mediates its analgesic effect by inhibiting the production of inflammatory mediators that sensitize nociceptive nerve endings and generate pain [5].

TargetActionsOrganism
AProstaglandin G/H synthase 1
inhibitor
Human
AProstaglandin G/H synthase 2
inhibitor
Human
Absorption

Following topical administration of 10% trolamine salicylate in healthy volunteers, salicylic acid could not be detected in serum indicating low systemic absorption [3].

Volume of distribution

Topical administration of 1 gram of 10% trolamine salicylate in abdominal rat skin resulted in an approximate extravascular volume of distribution (V/F) of 24.0 mL [4].

Protein binding
Not Available
Metabolism
Not Available
Route of elimination

Following topical administration of 10% trolamine salicylate in healthy volunteers, urinary recovery of total salicylate during the first 24 hours was 6.9 mg (p < 0.05), which is 1.4% of total dose [3].

Half life
Not Available
Clearance
Not Available
Toxicity

It is hazardous in case of ingestion [MSDS]. The carcinogenicity, mutagenicity and effects on reproductive fertility of trolamine salicylate have not been reported.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(R)-warfarinTrolamine salicylate may increase the anticoagulant activities of (R)-warfarin.Experimental
(S)-WarfarinTrolamine salicylate may increase the anticoagulant activities of (S)-Warfarin.Experimental, Investigational
2,4-thiazolidinedioneTrolamine salicylate may increase the hypoglycemic activities of 2,4-thiazolidinedione.Investigational
4-hydroxycoumarinTrolamine salicylate may increase the anticoagulant activities of 4-hydroxycoumarin.Experimental
AbciximabThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Abciximab.Approved
AcarboseTrolamine salicylate may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololTrolamine salicylate may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Trolamine salicylate.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Trolamine salicylate.Approved, Experimental, Investigational
AcenocoumarolTrolamine salicylate may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetazolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Acetazolamide.Approved, Vet Approved
AcetohexamideTrolamine salicylate may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Trolamine salicylate.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Trolamine salicylate.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Trolamine salicylate.Approved, Vet Approved
AICA ribonucleotideTrolamine salicylate may increase the hypoglycemic activities of AICA ribonucleotide.Experimental, Investigational
AlaproclateAlaproclate may increase the antiplatelet activities of Trolamine salicylate.Experimental
AlbiglutideTrolamine salicylate may increase the hypoglycemic activities of Albiglutide.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Trolamine salicylate.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Alendronic acid.Approved
AliskirenThe risk or severity of renal failure and hypertension can be increased when Trolamine salicylate is combined with Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Trolamine salicylate.Experimental
AlogliptinTrolamine salicylate may increase the hypoglycemic activities of Alogliptin.Approved
AloxiprinThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aloxiprin is combined with Trolamine salicylate.Experimental
AlprenololTrolamine salicylate may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
AlteplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Alteplase.Approved
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Amcinonide.Approved
AmediplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Amediplase.Investigational
AMG-222Trolamine salicylate may increase the hypoglycemic activities of AMG-222.Investigational
AmikacinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Amikacin.Approved, Investigational, Vet Approved
AmilorideThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Amiloride.Approved
AminophenazoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Aminophenazone.Approved, Withdrawn
Aminosalicylic AcidThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic Acid is combined with Trolamine salicylate.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Trolamine salicylate.Approved
Ammonium chlorideThe serum concentration of Trolamine salicylate can be increased when it is combined with Ammonium chloride.Approved, Investigational, Vet Approved
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Trolamine salicylate.Approved, Investigational
AnagliptinTrolamine salicylate may increase the hypoglycemic activities of Anagliptin.Investigational
AnagrelideThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Anagrelide.Approved
AncrodThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Trolamine salicylate.Investigational
AnisodamineTrolamine salicylate may decrease the antihypertensive activities of Anisodamine.Investigational
AnistreplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Anistreplase.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Trolamine salicylate.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Antrafenine is combined with Trolamine salicylate.Approved
ApixabanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Apixaban.Approved
ApramycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Apramycin.Experimental, Vet Approved
ArbekacinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Arbekacin.Approved, Investigational
ArdeparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Argatroban.Approved, Investigational
ArotinololTrolamine salicylate may decrease the antihypertensive activities of Arotinolol.Investigational
AstaxanthinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Astaxanthin.Investigational
AtenololTrolamine salicylate may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Trolamine salicylate.Withdrawn
AzathioprineThe metabolism of Azathioprine can be decreased when combined with Trolamine salicylate.Approved
Azilsartan medoxomilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azilsartan medoxomil is combined with Trolamine salicylate.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Trolamine salicylate.Investigational
BacitracinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Bacitracin.Approved, Vet Approved
BalaglitazoneTrolamine salicylate may increase the hypoglycemic activities of Balaglitazone.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Trolamine salicylate.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololTrolamine salicylate may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Bekanamycin.Experimental
BemiparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Bemiparin.Approved, Investigational
Bempedoic acidTrolamine salicylate may increase the hypoglycemic activities of Bempedoic acid.Investigational
BenazeprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Benazepril.Approved, Investigational
BenazeprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Benazeprilat.Experimental
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Trolamine salicylate.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Trolamine salicylate.Approved
BenfluorexTrolamine salicylate may increase the hypoglycemic activities of Benfluorex.Investigational, Withdrawn
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Trolamine salicylate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Trolamine salicylate.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Trolamine salicylate.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Trolamine salicylate.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Trolamine salicylate.Approved, Withdrawn
BeraprostThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Beraprost.Investigational
BesifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Besifloxacin.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Betamethasone.Approved, Vet Approved
BetaxololTrolamine salicylate may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Trolamine salicylate.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Trolamine salicylate.Approved, Investigational
BevantololTrolamine salicylate may decrease the antihypertensive activities of Bevantolol.Approved
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Trolamine salicylate.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
BisoprololTrolamine salicylate may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Bivalirudin.Approved, Investigational
BopindololTrolamine salicylate may decrease the antihypertensive activities of Bopindolol.Approved
BosentanThe therapeutic efficacy of Bosentan can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Trolamine salicylate.Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Trolamine salicylate.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Trolamine salicylate.Approved
BrinaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Brinase.Experimental
BrinzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Brinzolamide.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trolamine salicylate.Approved
BromocriptineTrolamine salicylate may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BucindololTrolamine salicylate may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Trolamine salicylate.Approved, Experimental
BuflomedilThe risk or severity of adverse effects can be increased when Buflomedil is combined with Trolamine salicylate.Experimental
BuforminTrolamine salicylate may increase the hypoglycemic activities of Buformin.Investigational, Withdrawn
BufuralolTrolamine salicylate may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Trolamine salicylate.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Trolamine salicylate.Approved
BupranololTrolamine salicylate may decrease the antihypertensive activities of Bupranolol.Approved
ButylphthalideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Trolamine salicylate.Investigational
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Trolamine salicylate.Experimental
CanagliflozinTrolamine salicylate may increase the hypoglycemic activities of Canagliflozin.Approved
CandesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan is combined with Trolamine salicylate.Experimental
Candesartan cilexetilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Candesartan cilexetil is combined with Trolamine salicylate.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Trolamine salicylate.Experimental
CangrelorThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Cangrelor.Approved
CapreomycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Capreomycin.Approved
CaptoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Trolamine salicylate.Experimental, Investigational
CarboplatinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Trolamine salicylate.Approved
CarbutamideTrolamine salicylate may increase the hypoglycemic activities of Carbutamide.Experimental
CarmegliptinTrolamine salicylate may increase the hypoglycemic activities of Carmegliptin.Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Trolamine salicylate.Approved, Vet Approved, Withdrawn
CarteololTrolamine salicylate may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolTrolamine salicylate may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CefacetrileThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Cefaclor is combined with Trolamine salicylate.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Cefamandole is combined with Trolamine salicylate.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Cefbuperazone is combined with Trolamine salicylate.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Cefcapene is combined with Trolamine salicylate.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Cefditoren is combined with Trolamine salicylate.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Cefepime is combined with Trolamine salicylate.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Cefetamet is combined with Trolamine salicylate.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Cefmenoxime is combined with Trolamine salicylate.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Cefmetazole is combined with Trolamine salicylate.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Cefminox is combined with Trolamine salicylate.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Cefodizime is combined with Trolamine salicylate.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Cefonicid is combined with Trolamine salicylate.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Cefoperazone is combined with Trolamine salicylate.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Ceforanide is combined with Trolamine salicylate.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Cefotaxime is combined with Trolamine salicylate.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Cefotetan is combined with Trolamine salicylate.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Cefotiam is combined with Trolamine salicylate.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Trolamine salicylate.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Cefozopran is combined with Trolamine salicylate.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Cefpiramide is combined with Trolamine salicylate.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Cefpirome is combined with Trolamine salicylate.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Cefpodoxime is combined with Trolamine salicylate.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Cefprozil is combined with Trolamine salicylate.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Cefsulodin is combined with Trolamine salicylate.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Ceftazidime is combined with Trolamine salicylate.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Ceftibuten is combined with Trolamine salicylate.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Ceftizoxime is combined with Trolamine salicylate.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Ceftriaxone is combined with Trolamine salicylate.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Cefuroxime is combined with Trolamine salicylate.Approved
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Trolamine salicylate.Approved, Investigational
CeliprololTrolamine salicylate may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Cephalothin Group.Experimental
CertoparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Certoparin.Approved, Investigational
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
ChlorpropamideTrolamine salicylate may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Trolamine salicylate.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Trolamine salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Trolamine salicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ciclesonide.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Trolamine salicylate.Investigational
CiglitazoneTrolamine salicylate may increase the hypoglycemic activities of Ciglitazone.Experimental
CilazaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Cilazapril.Approved
CilostazolThe risk or severity of adverse effects can be increased when Cilostazol is combined with Trolamine salicylate.Approved, Investigational
CimicoxibThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cimicoxib.Investigational
CinoxacinTrolamine salicylate may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinTrolamine salicylate may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Trolamine salicylate.Approved
CitalopramCitalopram may increase the antiplatelet activities of Trolamine salicylate.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Trolamine salicylate.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Trolamine salicylate.Approved
ClopidogrelThe risk or severity of adverse effects can be increased when Clopidogrel is combined with Trolamine salicylate.Approved
CloprednolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cloprednol.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Trolamine salicylate.Vet Approved
CloranololTrolamine salicylate may decrease the antihypertensive activities of Cloranolol.Experimental
CloricromenThe risk or severity of adverse effects can be increased when Cloricromen is combined with Trolamine salicylate.Experimental
ClorindioneTrolamine salicylate may increase the anticoagulant activities of Clorindione.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Trolamine salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Trolamine salicylate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColistimethateThe risk or severity of nephrotoxicity can be increased when Colistimethate is combined with Trolamine salicylate.Approved, Vet Approved
CorticotropinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Corticotropin.Approved, Investigational, Vet Approved
Cortisone acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cortisone acetate.Approved, Investigational
CortivazolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Cortivazol.Investigational
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Trolamine salicylate.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Trolamine salicylate.Experimental
CyclosporineThe risk or severity of renal failure and hypertension can be increased when Trolamine salicylate is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Trolamine salicylate.Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Trolamine salicylate.Experimental
Dabigatran etexilateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dabigatran etexilate.Approved
DalteparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dalteparin.Approved
DanaparoidThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Danaparoid.Approved, Withdrawn
DapagliflozinTrolamine salicylate may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetineDapoxetine may increase the antiplatelet activities of Trolamine salicylate.Investigational
DarexabanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Darexaban.Investigational
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
DeferasiroxThe risk or severity of gastrointestinal bleeding and peptic ulcer can be increased when Trolamine salicylate is combined with Deferasirox.Approved, Investigational
DefibrotideThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Defibrotide.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Delapril.Investigational
DersalazineThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Dersalazine is combined with Trolamine salicylate.Investigational
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Trolamine salicylate.Approved
DesirudinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Desirudin.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Trolamine salicylate.Approved
DesmopressinThe risk or severity of hypertension, hyponatremia, and water intoxication can be increased when Trolamine salicylate is combined with Desmopressin.Approved
DesmoteplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Desmoteplase.Investigational
DesonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Desoximetasone.Approved
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Dexibuprofen is combined with Trolamine salicylate.Approved, Investigational
DexketoprofenThe risk or severity of bleeding and gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Dexketoprofen.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Trolamine salicylate.Experimental
DextranThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dextran.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Trolamine salicylate.Approved
DibekacinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Dibekacin.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Trolamine salicylate.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Diclofenamide.Approved, Investigational
DicoumarolTrolamine salicylate may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Trolamine salicylate.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Trolamine salicylate.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Diflorasone.Approved
DifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Difloxacin.Vet Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Trolamine salicylate.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Difluprednate.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Trolamine salicylate.Approved, Investigational
DigoxinTrolamine salicylate may decrease the excretion rate of Digoxin which could result in a higher serum level.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
DihydrostreptomycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Dihydrostreptomycin.Investigational, Vet Approved
DiltiazemDiltiazem may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Trolamine salicylate.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Trolamine salicylate.Approved
DiphenadioneTrolamine salicylate may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Dipyridamole.Approved
DisopyramideTrolamine salicylate may increase the hypoglycemic activities of Disopyramide.Approved
DitazoleThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ditazole.Approved, Withdrawn
DorzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Dorzolamide.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Trolamine salicylate.Approved
DrospirenoneThe risk or severity of hyperkalemia can be increased when Trolamine salicylate is combined with Drospirenone.Approved
Drotrecogin alfaThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Trolamine salicylate.Withdrawn
DulaglutideTrolamine salicylate may increase the hypoglycemic activities of Dulaglutide.Approved, Investigational
DuloxetineDuloxetine may increase the antiplatelet activities of Trolamine salicylate.Approved
DutogliptinTrolamine salicylate may increase the hypoglycemic activities of Dutogliptin.Investigational
Edetic AcidThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Edetic Acid.Approved, Vet Approved
EdoxabanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Edoxaban.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
EmpagliflozinTrolamine salicylate may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Enalaprilat.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Trolamine salicylate.Experimental
EnglitazoneTrolamine salicylate may increase the hypoglycemic activities of Englitazone.Experimental
EnoxacinTrolamine salicylate may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Trolamine salicylate.Experimental
EpanololTrolamine salicylate may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Trolamine salicylate.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Trolamine salicylate.Experimental
EplerenoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Epoprostenol.Approved
EprosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Trolamine salicylate.Approved
EptifibatideThe risk or severity of adverse effects can be increased when Eptifibatide is combined with Trolamine salicylate.Approved, Investigational
EsatenololTrolamine salicylate may decrease the antihypertensive activities of Esatenolol.Experimental
EscitalopramEscitalopram may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
EsmololTrolamine salicylate may decrease the antihypertensive activities of Esmolol.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Trolamine salicylate.Experimental
EthoxzolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ethoxzolamide.Withdrawn
Ethyl biscoumacetateTrolamine salicylate may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Trolamine salicylate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Trolamine salicylate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Trolamine salicylate.Approved, Investigational
EvogliptinTrolamine salicylate may increase the hypoglycemic activities of Evogliptin.Investigational
ExenatideTrolamine salicylate may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Trolamine salicylate.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Trolamine salicylate.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Trolamine salicylate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Trolamine salicylate.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Trolamine salicylate.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Trolamine salicylate.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Trolamine salicylate.Experimental
Ferulic acidThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ferulic acid.Experimental
FibrinolysinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Fibrinolysin.Investigational
FimasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fimasartan is combined with Trolamine salicylate.Approved, Investigational
FirocoxibThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Firocoxib.Experimental, Vet Approved
FleroxacinTrolamine salicylate may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Trolamine salicylate.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Flomoxef is combined with Trolamine salicylate.Investigational
FlucloroloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluclorolone.Experimental
FludrocortisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fludrocortisone.Approved, Investigational
FluindioneTrolamine salicylate may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineTrolamine salicylate may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Trolamine salicylate.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Trolamine salicylate.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocinonide.Approved, Investigational
FluocortinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocortin.Experimental
FluocortoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluorometholone.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Trolamine salicylate.Approved, Vet Approved
FluperoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluperolone.Experimental
FluprednideneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Trolamine salicylate.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Trolamine salicylate.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Fluticasone propionate.Approved
FluvoxamineFluvoxamine may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
FondaparinuxThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Fondaparinux.Approved, Investigational
ForasartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Forasartan is combined with Trolamine salicylate.Experimental
FormocortalThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Formocortal.Experimental
FoscarnetThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Foscarnet.Approved
FosinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Fosinopril.Approved
FosinoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Fosinoprilat.Experimental
FramycetinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Framycetin.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
GabexateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Gabexate.Investigational
GarenoxacinTrolamine salicylate may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Trolamine salicylate.Approved, Withdrawn
GemifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GemigliptinTrolamine salicylate may increase the hypoglycemic activities of Gemigliptin.Investigational
GeneticinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Geneticin.Experimental
GentamicinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with GENTAMICIN C1A.Experimental
Ginkgo bilobaGinkgo biloba may increase the anticoagulant activities of Trolamine salicylate.Approved, Investigational, Nutraceutical
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Trolamine salicylate.Experimental
GlibornurideTrolamine salicylate may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideTrolamine salicylate may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideTrolamine salicylate may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideTrolamine salicylate may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneTrolamine salicylate may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideTrolamine salicylate may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideTrolamine salicylate may increase the hypoglycemic activities of Glyburide.Approved
GlycodiazineTrolamine salicylate may increase the hypoglycemic activities of Glycodiazine.Approved, Investigational
GosogliptinTrolamine salicylate may increase the hypoglycemic activities of Gosogliptin.Investigational
GrepafloxacinTrolamine salicylate may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Trolamine salicylate.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Trolamine salicylate.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Trolamine salicylate.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Trolamine salicylate.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Trolamine salicylate.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Trolamine salicylate.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Trolamine salicylate.Experimental
Guar gumTrolamine salicylate may increase the hypoglycemic activities of Guar gum.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Halcinonide.Approved, Investigational, Withdrawn
HalometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Halometasone.Experimental
HaloperidolThe therapeutic efficacy of Haloperidol can be increased when used in combination with Trolamine salicylate.Approved
HeparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Heparin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Trolamine salicylate.Experimental
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
HydralazineTrolamine salicylate may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone aceponateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone aceponate.Experimental, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone butyrate.Approved, Vet Approved
Hydrocortisone probutateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone probutate.Approved, Vet Approved
Hydrocortisone succinateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone succinate.Approved
Hydrocortisone valerateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Hydrocortisone valerate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Hydrolyzed Cephalothin.Experimental
HydroxytyrosolThe risk or severity of adverse effects can be increased when Hydroxytyrosol is combined with Trolamine salicylate.Investigational
Hygromycin BThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Hygromycin B.Vet Approved
IbandronateThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Ibandronate.Approved, Investigational
IbudilastThe risk or severity of adverse effects can be increased when Ibudilast is combined with Trolamine salicylate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Trolamine salicylate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Trolamine salicylate.Withdrawn
IcosapentThe risk or severity of adverse effects can be increased when Icosapent is combined with Trolamine salicylate.Approved, Nutraceutical
Icosapent ethylThe risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Trolamine salicylate.Approved, Investigational, Nutraceutical
IdraparinuxThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Idraparinux.Investigational
IfetrobanThe risk or severity of adverse effects can be increased when Ifetroban is combined with Trolamine salicylate.Investigational
IloprostThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Trolamine salicylate.Experimental
Incadronic acidThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Incadronic acid.Approved, Investigational
IndalpineIndalpine may increase the antiplatelet activities of Trolamine salicylate.Investigational, Withdrawn
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Trolamine salicylate.Approved
IndenololTrolamine salicylate may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Trolamine salicylate.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trolamine salicylate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Trolamine salicylate.Withdrawn
IndoraminThe therapeutic efficacy of Indoramin can be decreased when used in combination with Trolamine salicylate.Withdrawn
Influenza Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Influenza Vaccine (Live/Attenuated) is combined with Trolamine salicylate.Approved
Insulin AspartTrolamine salicylate may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin BeefTrolamine salicylate may increase the hypoglycemic activities of Insulin Beef.Approved
Insulin DegludecTrolamine salicylate may increase the hypoglycemic activities of Insulin Degludec.Approved
Insulin DetemirTrolamine salicylate may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlargineTrolamine salicylate may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisineTrolamine salicylate may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanTrolamine salicylate may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproTrolamine salicylate may increase the hypoglycemic activities of Insulin Lispro.Approved
Insulin peglisproTrolamine salicylate may increase the hypoglycemic activities of Insulin peglispro.Investigational
Insulin PorkTrolamine salicylate may increase the hypoglycemic activities of Insulin Pork.Approved
IrbesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Irbesartan is combined with Trolamine salicylate.Approved, Investigational
IsepamicinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Isepamicin.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Trolamine salicylate.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
KanamycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Kanamycin.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Trolamine salicylate.Experimental
KetanserinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Trolamine salicylate.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Trolamine salicylate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Trolamine salicylate.Approved
KRP-104Trolamine salicylate may increase the hypoglycemic activities of KRP-104.Investigational
LabetalolTrolamine salicylate may decrease the antihypertensive activities of Labetalol.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Trolamine salicylate.Experimental
LandiololTrolamine salicylate may decrease the antihypertensive activities of Landiolol.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Latamoxef is combined with Trolamine salicylate.Approved, Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
LepirudinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Lepirudin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
LetaxabanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Letaxaban.Investigational
LevobetaxololTrolamine salicylate may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololTrolamine salicylate may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinTrolamine salicylate may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
LinagliptinTrolamine salicylate may increase the hypoglycemic activities of Linagliptin.Approved
LinsidomineThe risk or severity of adverse effects can be increased when Linsidomine is combined with Trolamine salicylate.Experimental
LiraglutideTrolamine salicylate may increase the hypoglycemic activities of Liraglutide.Approved
LisinoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Lisinopril.Approved, Investigational
Lithium cationTrolamine salicylate may decrease the excretion rate of Lithium cation which could result in a higher serum level.Experimental
LixisenatideTrolamine salicylate may increase the hypoglycemic activities of Lixisenatide.Approved
LobeglitazoneTrolamine salicylate may increase the hypoglycemic activities of Lobeglitazone.Approved, Investigational
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
LomefloxacinTrolamine salicylate may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Trolamine salicylate.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Loracarbef is combined with Trolamine salicylate.Investigational, Withdrawn
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Trolamine salicylate.Approved, Investigational
LosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Losartan is combined with Trolamine salicylate.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Trolamine salicylate.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Trolamine salicylate.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Trolamine salicylate.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Trolamine salicylate.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trolamine salicylate.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Trolamine salicylate.Approved, Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
MecaserminTrolamine salicylate may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trolamine salicylate.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Trolamine salicylate.Approved
MelagatranThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Trolamine salicylate.Approved, Vet Approved
MepindololTrolamine salicylate may decrease the antihypertensive activities of Mepindolol.Experimental
MeprednisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Meprednisone.Approved, Investigational
MercaptopurineThe metabolism of Mercaptopurine can be decreased when combined with Trolamine salicylate.Approved
MesalazineThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mesalazine.Approved
MetahexamideTrolamine salicylate may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
MetforminTrolamine salicylate may increase the hypoglycemic activities of Metformin.Approved
MethazolamideThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Methazolamide.Approved
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Trolamine salicylate.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trolamine salicylate.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Trolamine salicylate.Approved
Methyl salicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Methyl salicylate is combined with Trolamine salicylate.Approved, Vet Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Trolamine salicylate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Methylprednisolone.Approved, Vet Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Trolamine salicylate.Experimental
MetipranololTrolamine salicylate may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Trolamine salicylate.Approved
MetoprololTrolamine salicylate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Trolamine salicylate.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Trolamine salicylate.Investigational, Withdrawn
MicronomicinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Micronomicin.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Trolamine salicylate.Approved, Experimental
MifepristoneTrolamine salicylate may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolTrolamine salicylate may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranMilnacipran may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Trolamine salicylate.Approved
MitiglinideTrolamine salicylate may increase the hypoglycemic activities of Mitiglinide.Approved, Investigational
MoexiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Trolamine salicylate.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone.Approved, Vet Approved
Mometasone furoateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone furoate.Approved, Vet Approved
Monopotassium phosphateThe serum concentration of Trolamine salicylate can be increased when it is combined with Monopotassium phosphate.Approved, Investigational, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Morniflumate.Approved
MoxifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Trolamine salicylate.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Trolamine salicylate.Approved
NadololTrolamine salicylate may decrease the antihypertensive activities of Nadolol.Approved
NadroparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Nadroparin.Approved, Investigational
NafamostatThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Nafamostat.Approved, Investigational
NaftopidilThe risk or severity of adverse effects can be increased when Naftopidil is combined with Trolamine salicylate.Investigational
Nalidixic AcidTrolamine salicylate may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Trolamine salicylate.Approved, Vet Approved
NateglinideTrolamine salicylate may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NBI-6024Trolamine salicylate may increase the hypoglycemic activities of NBI-6024.Investigational
NeamineThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Neamine.Experimental
NebivololTrolamine salicylate may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneNefazodone may increase the antiplatelet activities of Trolamine salicylate.Approved, Withdrawn
NemonoxacinTrolamine salicylate may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Neomycin.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Trolamine salicylate.Approved, Investigational
NetilmicinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Netilmicin.Approved, Investigational
NetoglitazoneTrolamine salicylate may increase the hypoglycemic activities of Netoglitazone.Experimental
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Trolamine salicylate.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Trolamine salicylate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Trolamine salicylate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Trolamine salicylate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Nitroaspirin.Investigational
NitroprussideThe therapeutic efficacy of Nitroprusside can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
NN344Trolamine salicylate may increase the hypoglycemic activities of NN344.Investigational
NorfloxacinTrolamine salicylate may increase the neuroexcitatory activities of Norfloxacin.Approved
NS-398The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with NS-398.Experimental
OfloxacinTrolamine salicylate may increase the neuroexcitatory activities of Ofloxacin.Approved
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Trolamine salicylate.Experimental, Investigational
OlmesartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Olmesartan is combined with Trolamine salicylate.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Trolamine salicylate.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Omapatrilat.Investigational
OmarigliptinTrolamine salicylate may increase the hypoglycemic activities of Omarigliptin.Investigational
OrbifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Orbifloxacin.Vet Approved
OtamixabanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Otamixaban.Investigational
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Trolamine salicylate.Approved
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trolamine salicylate.Approved
Oxolinic acidTrolamine salicylate may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololTrolamine salicylate may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Trolamine salicylate.Approved, Withdrawn
PamidronateThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Trolamine salicylate.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Trolamine salicylate.Approved
ParnaparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Parnaparin.Approved, Investigational
ParomomycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Paromomycin.Approved, Investigational
ParoxetineParoxetine may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
PazufloxacinTrolamine salicylate may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinTrolamine salicylate may increase the neuroexcitatory activities of Pefloxacin.Approved
PemetrexedThe serum concentration of Pemetrexed can be increased when it is combined with Trolamine salicylate.Approved, Investigational
PenbutololTrolamine salicylate may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
PentamidineTrolamine salicylate may increase the hypoglycemic activities of Pentamidine.Approved, Investigational
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Trolamine salicylate.Approved
Pentosan PolysulfateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Pentosan Polysulfate.Approved
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentoxifylline is combined with Trolamine salicylate.Approved, Investigational
PerindoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Perindopril.Approved
PerindoprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Perindoprilat.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Trolamine salicylate.Experimental
PhenforminTrolamine salicylate may increase the hypoglycemic activities of Phenformin.Approved, Investigational, Withdrawn
PhenindioneTrolamine salicylate may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenoxybenzamineThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Trolamine salicylate.Approved
PhenprocoumonTrolamine salicylate may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineThe therapeutic efficacy of Phentolamine can be decreased when used in combination with Trolamine salicylate.Approved
Phenyl aminosalicylateThe risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Phenyl aminosalicylate is combined with Trolamine salicylate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Trolamine salicylate.Approved, Vet Approved
PicotamideThe risk or severity of adverse effects can be increased when Picotamide is combined with Trolamine salicylate.Experimental
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Trolamine salicylate.Approved
PindololTrolamine salicylate may decrease the antihypertensive activities of Pindolol.Approved, Investigational
PioglitazoneTrolamine salicylate may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
Pipemidic acidTrolamine salicylate may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Trolamine salicylate.Approved
Piromidic acidTrolamine salicylate may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trolamine salicylate.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Trolamine salicylate.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Pitolisant.Approved, Investigational
PlazomicinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Plazomicin.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Trolamine salicylate.Approved
Potassium CitrateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Potassium Citrate.Approved, Investigational, Vet Approved
PractololTrolamine salicylate may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trolamine salicylate.Approved, Investigational
PramlintideTrolamine salicylate may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Trolamine salicylate.Experimental, Investigational
PrasugrelThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Prasugrel.Approved
PrazosinThe therapeutic efficacy of Prazosin can be decreased when used in combination with Trolamine salicylate.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednisone.Approved, Vet Approved
PrednylideneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Prednylidene.Experimental
ProbenecidThe therapeutic efficacy of Probenecid can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Trolamine salicylate.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Trolamine salicylate.Approved, Investigational
PropafenoneTrolamine salicylate may decrease the antihypertensive activities of Propafenone.Approved
PropranololTrolamine salicylate may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Trolamine salicylate.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Trolamine salicylate.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Trolamine salicylate.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Trolamine salicylate.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Trolamine salicylate.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Trolamine salicylate.Vet Approved
Protein CThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Protein C.Approved
Protein S humanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Protein S human.Approved
ProtocatechualdehydeThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Protocatechualdehyde.Approved
PrulifloxacinTrolamine salicylate may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PuromycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Puromycin.Experimental
QuinaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Quinapril.Approved, Investigational
QuinaprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Quinaprilat.Experimental
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Trolamine salicylate.Approved
QuinineTrolamine salicylate may increase the hypoglycemic activities of Quinine.Approved
RamatrobanThe risk or severity of adverse effects can be increased when Ramatroban is combined with Trolamine salicylate.Investigational
RamiprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Ramipril.Approved
RamiprilatThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Ramiprilat.Experimental
RelcovaptanThe risk or severity of adverse effects can be increased when Relcovaptan is combined with Trolamine salicylate.Investigational
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Trolamine salicylate.Approved
RepaglinideTrolamine salicylate may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnamineThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Rescinnamine.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Trolamine salicylate.Approved, Experimental, Investigational
ReteplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Reteplase.Approved, Investigational
ReviparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Reviparin.Approved, Investigational
RibostamycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Ribostamycin.Approved, Investigational
RidogrelThe risk or severity of adverse effects can be increased when Ridogrel is combined with Trolamine salicylate.Approved
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Rimexolone.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Trolamine salicylate.Approved
RisedronateThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Risedronate.Approved, Investigational
RitanserinRitanserin may increase the antiplatelet activities of Trolamine salicylate.Investigational
RivaroxabanThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Rivaroxaban.Approved
RivoglitazoneTrolamine salicylate may increase the hypoglycemic activities of Rivoglitazone.Experimental, Investigational
RobenacoxibThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Robenacoxib.Experimental, Vet Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
RosiglitazoneTrolamine salicylate may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
RosoxacinTrolamine salicylate may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinTrolamine salicylate may increase the neuroexcitatory activities of Rufloxacin.Experimental
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Trolamine salicylate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Trolamine salicylate.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Trolamine salicylate.Approved
SaprisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Trolamine salicylate.Experimental
SarafloxacinTrolamine salicylate may increase the neuroexcitatory activities of Sarafloxacin.Vet Approved, Withdrawn
SaralasinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saralasin is combined with Trolamine salicylate.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Sarpogrelate is combined with Trolamine salicylate.Investigational
SaruplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Saruplase.Experimental
SaxagliptinTrolamine salicylate may increase the hypoglycemic activities of Saxagliptin.Approved
SC-236The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with SC-236.Experimental, Investigational
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Trolamine salicylate.Approved
SemaglutideTrolamine salicylate may increase the hypoglycemic activities of Semaglutide.Approved, Investigational
SertralineSertraline may increase the antiplatelet activities of Trolamine salicylate.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Trolamine salicylate.Approved, Vet Approved
SibutramineSibutramine may increase the antiplatelet activities of Trolamine salicylate.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Sisomicin.Investigational
SitafloxacinTrolamine salicylate may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitagliptinTrolamine salicylate may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Trolamine salicylate.Approved, Investigational, Withdrawn
Sodium CitrateThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Sodium Citrate.Approved, Investigational
Sodium phosphate, monobasicThe risk or severity of renal failure can be increased when Sodium phosphate, monobasic is combined with Trolamine salicylate.Approved
SotagliflozinTrolamine salicylate may increase the hypoglycemic activities of Sotagliflozin.Investigational
SotalolTrolamine salicylate may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinTrolamine salicylate may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Spirapril.Approved
SpironolactoneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Spironolactone.Approved
StreptokinaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Streptokinase.Approved, Investigational
StreptomycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Streptomycin.Approved, Vet Approved
SulfadiazineTrolamine salicylate may increase the hypoglycemic activities of Sulfadiazine.Approved, Investigational, Vet Approved
SulfamethoxazoleTrolamine salicylate may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trolamine salicylate.Approved
SulfinpyrazoneThe risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Trolamine salicylate.Approved
SulfisoxazoleTrolamine salicylate may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Trolamine salicylate.Approved, Investigational
SulodexideThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Trolamine salicylate.Investigational
SunitinibTrolamine salicylate may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Trolamine salicylate.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Trolamine salicylate.Experimental
TacrolimusThe risk or severity of renal failure can be increased when Trolamine salicylate is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Trolamine salicylate.Approved
TalinololTrolamine salicylate may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Talniflumate.Approved
TasosartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tasosartan is combined with Trolamine salicylate.Approved
TaspoglutideTrolamine salicylate may increase the hypoglycemic activities of Taspoglutide.Investigational
Technetium Tc-99m ciprofloxacinTrolamine salicylate may increase the neuroexcitatory activities of Technetium Tc-99m ciprofloxacin.Investigational
TelmisartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Telmisartan is combined with Trolamine salicylate.Approved, Investigational
TemafloxacinTrolamine salicylate may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Temocapril.Experimental, Investigational
TenecteplaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Tenecteplase.Approved
TeneligliptinTrolamine salicylate may increase the hypoglycemic activities of Teneligliptin.Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Trolamine salicylate.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Trolamine salicylate.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Trolamine salicylate.Approved
Tenofovir disoproxilTrolamine salicylate may decrease the excretion rate of Tenofovir disoproxil which could result in a higher serum level.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Trolamine salicylate.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Trolamine salicylate.Vet Approved
TerazosinThe therapeutic efficacy of Terazosin can be decreased when used in combination with Trolamine salicylate.Approved
TertatololTrolamine salicylate may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneThe risk or severity of adverse effects can be increased when Tesmilifene is combined with Trolamine salicylate.Investigational
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Trolamine salicylate.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Trolamine salicylate.Approved
TicagrelorThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ticagrelor.Approved
TiclopidineThe risk or severity of adverse effects can be increased when Ticlopidine is combined with Trolamine salicylate.Approved
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Trolamine salicylate.Withdrawn
Tiludronic acidThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTrolamine salicylate may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Trolamine salicylate.Investigational
TinzaparinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Tinzaparin.Approved
TioclomarolTrolamine salicylate may increase the anticoagulant activities of Tioclomarol.Experimental
TioguanineThe metabolism of Tioguanine can be decreased when combined with Trolamine salicylate.Approved
TirofibanThe risk or severity of adverse effects can be increased when Tirofiban is combined with Trolamine salicylate.Approved
TixocortolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Tixocortol.Approved, Withdrawn
TobramycinThe risk or severity of nephrotoxicity can be increased when Trolamine salicylate is combined with Tobramycin.Approved, Investigational
TocopherylquinoneThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Tocopherylquinone.Experimental, Investigational
TolazamideTrolamine salicylate may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
TolbutamideTrolamine salicylate may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Trolamine salicylate.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trolamine salicylate.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Trolamine salicylate.Experimental
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Trolamine salicylate.Approved
TrandolaprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Trolamine salicylate.Approved, Investigational
TrapidilThe risk or severity of adverse effects can be increased when Trapidil is combined with Trolamine salicylate.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Trolamine salicylate.Approved
TrazodoneTrazodone may increase the antiplatelet activities of Trolamine salicylate.Approved, Investigational
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trolamine salicylate.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Triamterene.Approved
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Trolamine salicylate.Approved, Vet Approved
TriflusalThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Triflusal.Approved, Investigational
TrilostaneThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimazosinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Trolamine salicylate.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
TroglitazoneTrolamine salicylate may increase the hypoglycemic activities of Troglitazone.Investigational, Withdrawn
TrovafloxacinTrolamine salicylate may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Trolamine salicylate.Approved, Investigational
UrapidilThe therapeutic efficacy of Urapidil can be decreased when used in combination with Trolamine salicylate.Investigational
UrokinaseThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Trolamine salicylate.Approved, Investigational, Withdrawn
Valproic AcidThe serum concentration of Valproic Acid can be increased when it is combined with Trolamine salicylate.Approved, Investigational
ValsartanThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valsartan is combined with Trolamine salicylate.Approved, Investigational
VancomycinTrolamine salicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Trolamine salicylate.Approved
VerapamilVerapamil may increase the anticoagulant activities of Trolamine salicylate.Approved
VildagliptinTrolamine salicylate may increase the hypoglycemic activities of Vildagliptin.Approved, Investigational
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Trolamine salicylate.Experimental
VogliboseTrolamine salicylate may increase the hypoglycemic activities of Voglibose.Approved, Investigational
VorapaxarThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Vorapaxar.Approved
WarfarinTrolamine salicylate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe risk or severity of bleeding can be increased when Trolamine salicylate is combined with Ximelagatran.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Trolamine salicylate.Experimental
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Trolamine salicylate.Approved, Investigational
ZimelidineZimelidine may increase the antiplatelet activities of Trolamine salicylate.Withdrawn
ZofenoprilThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Trolamine salicylate is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of gastrointestinal bleeding can be increased when Trolamine salicylate is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Trolamine salicylate.Withdrawn
Food Interactions
Not Available

References

General References
  1. Rothacker DQ, Lee I, Littlejohn TW 3rd: Effectiveness of a single topical application of 10|x% trolamine salicylate cream in the symptomatic treatment of osteoarthritis. J Clin Rheumatol. 1998 Feb;4(1):6-12. [PubMed:19078236]
  2. Hill DW, Richardson JD: Effectiveness of 10% trolamine salicylate cream on muscular soreness induced by a reproducible program of weight training. J Orthop Sports Phys Ther. 1989;11(1):19-23. [PubMed:18796932]
  3. Morra P, Bartle WR, Walker SE, Lee SN, Bowles SK, Reeves RA: Serum concentrations of salicylic acid following topically applied salicylate derivatives. Ann Pharmacother. 1996 Sep;30(9):935-40. doi: 10.1177/106002809603000903. [PubMed:8876850]
  4. Sajjadi P, Khodayar MJ, Sharif Makhmalzadeh B, Rezaee S: Percutaneous absorption of salicylic Acid after administration of trolamine salicylate cream in rats with transcutol((R)) and eucalyptus oil pre-treated skin. Adv Pharm Bull. 2013;3(2):295-301. doi: 10.5681/apb.2013.048. Epub 2013 Aug 20. [PubMed:24312851]
  5. 26. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 318-322). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  6. Health Canada: Triethanolamine Salicylate (Trolamine) Label [Link]
External Links
PubChem Compound
25213
PubChem Substance
347827887
ChemSpider
23549
ChEMBL
CHEMBL2107288
Wikipedia
Trolamine_salicylate
AHFS Codes
  • 28:08.04.24 — Salicylates
MSDS
Download (47.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingTreatmentMinor burns1
2TerminatedTreatmentToothache1
3CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPain, Neuropathic1
4CompletedTreatmentCaudal epidural block therapy / Forearm Injuries / Orthopedic Procedures / Traumas / Upper Extremity1
4CompletedTreatmentCaudal epidural block therapy / Orthopedic Procedures / Shoulder1
Not AvailableCompletedTreatmentCerebral Palsy (CP)1
Not AvailableCompletedTreatmentErectile Dysfunction (ED)1
Not AvailableCompletedTreatmentRecession, Gingival1
Not AvailableRecruitingBasic ScienceHeart Failure, Unspecified1
Not AvailableRecruitingTreatmentCervical Osteoarthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CreamTopical10 g/100mL
OintmentTopical13.3 %
CreamTopical10 g/100g
LotionTopical10 %
SprayTopical100 mg/mL
SprayTopical.1 g/100mL
CreamTopical8.5 g/85g
SprayTopical10 g/100mL
LiquidTopical10 g/100g
GelTopical15 %
LotionTopical
LotionTopical10.0 %
CreamTopical
CreamTopical13.3 %
CreamTopical15 %
CreamTopical100 mg/g
PatchTopical12.5 %
GelTopical
CreamCutaneous10 g/1
CreamTopical20 %
PatchTopical
CreamTopical10 %
LotionTopical10 g/100mL
LiquidTopical100 mg/mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
PropertyValueSource
melting point (°C)50MSDS
boiling point (°C)DecomposesMSDS
water solubilitySolubleMSDS
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP1.96ALOGPS
logP1.98ChemAxon
logS-1.1ALOGPS
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area57.53 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity35.3 m3·mol-1ChemAxon
Polarizability12.82 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,2-aminoalcohols. These are organic compounds containing an alkyl chain with an amine group bound to the C1 atom and an alcohol group bound to the C2 atom.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
1,2-aminoalcohols
Alternative Parents
Trialkylamines / Monocarboxylic acids and derivatives / Primary alcohols / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tertiary aliphatic amine / Tertiary amine / 1,2-aminoalcohol / Monocarboxylic acid or derivatives / Organic oxygen compound / Organopnictogen compound / Hydrocarbon derivative / Primary alcohol / Organooxygen compound / Alcohol
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Topical Analgesic and Anesthetic Agents Drug Class Review [Link]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Topical Analgesic and Anesthetic Agents Drug Class Review [Link]

Drug created on December 03, 2015 09:51 / Updated on August 14, 2018 04:32